The Role of Endoscopic Intra-Gastric Botulinum Toxin-A for Obesity Treatment

Hadya Elshakh, Khalid El-Ejji, Shahrad Taheri

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Obesity prevalence has been increasing with devastating health and economic consequences. Botulinum toxin type A (BTX-A), a neurotoxin, is used clinically for conditions characterized by prolonged muscular contraction. Its inhibitory effects on gastric smooth muscles, in theory, make it a potential agent for obesity treatment through delayed gastric emptying and increased satiety. This review aims to examine the evidence for the use of endoscopic BTX-A injection for treating obesity. The literature search identified 60 articles with 11 primary studies as relevant for the scope of the review. Several studies have been conducted to examine the effect of BTX-A injections on obesity, including both animal and human studies. Current evidence from identified studies does not demonstrate sustained weight loss through the use of endoscopic BTX-A injection.

Original languageEnglish
Pages (from-to)2471-2478
Number of pages8
JournalObesity Surgery
Volume27
Issue number9
DOIs
Publication statusPublished - 1 Sep 2017

Fingerprint

Type A Botulinum Toxins
Stomach
Obesity
Injections
Gastric Emptying
Neurotoxins
Therapeutics
Muscle Contraction
Smooth Muscle
Weight Loss
Economics
Health

Keywords

  • Botulinum toxin-A
  • Endoscopy
  • Obesity

ASJC Scopus subject areas

  • Surgery
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

The Role of Endoscopic Intra-Gastric Botulinum Toxin-A for Obesity Treatment. / Elshakh, Hadya; El-Ejji, Khalid; Taheri, Shahrad.

In: Obesity Surgery, Vol. 27, No. 9, 01.09.2017, p. 2471-2478.

Research output: Contribution to journalReview article

Elshakh, Hadya ; El-Ejji, Khalid ; Taheri, Shahrad. / The Role of Endoscopic Intra-Gastric Botulinum Toxin-A for Obesity Treatment. In: Obesity Surgery. 2017 ; Vol. 27, No. 9. pp. 2471-2478.
@article{7d657b65ae1348dbbc96108658069eda,
title = "The Role of Endoscopic Intra-Gastric Botulinum Toxin-A for Obesity Treatment",
abstract = "Obesity prevalence has been increasing with devastating health and economic consequences. Botulinum toxin type A (BTX-A), a neurotoxin, is used clinically for conditions characterized by prolonged muscular contraction. Its inhibitory effects on gastric smooth muscles, in theory, make it a potential agent for obesity treatment through delayed gastric emptying and increased satiety. This review aims to examine the evidence for the use of endoscopic BTX-A injection for treating obesity. The literature search identified 60 articles with 11 primary studies as relevant for the scope of the review. Several studies have been conducted to examine the effect of BTX-A injections on obesity, including both animal and human studies. Current evidence from identified studies does not demonstrate sustained weight loss through the use of endoscopic BTX-A injection.",
keywords = "Botulinum toxin-A, Endoscopy, Obesity",
author = "Hadya Elshakh and Khalid El-Ejji and Shahrad Taheri",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s11695-017-2806-3",
language = "English",
volume = "27",
pages = "2471--2478",
journal = "Obesity Surgery",
issn = "0960-8923",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - The Role of Endoscopic Intra-Gastric Botulinum Toxin-A for Obesity Treatment

AU - Elshakh, Hadya

AU - El-Ejji, Khalid

AU - Taheri, Shahrad

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Obesity prevalence has been increasing with devastating health and economic consequences. Botulinum toxin type A (BTX-A), a neurotoxin, is used clinically for conditions characterized by prolonged muscular contraction. Its inhibitory effects on gastric smooth muscles, in theory, make it a potential agent for obesity treatment through delayed gastric emptying and increased satiety. This review aims to examine the evidence for the use of endoscopic BTX-A injection for treating obesity. The literature search identified 60 articles with 11 primary studies as relevant for the scope of the review. Several studies have been conducted to examine the effect of BTX-A injections on obesity, including both animal and human studies. Current evidence from identified studies does not demonstrate sustained weight loss through the use of endoscopic BTX-A injection.

AB - Obesity prevalence has been increasing with devastating health and economic consequences. Botulinum toxin type A (BTX-A), a neurotoxin, is used clinically for conditions characterized by prolonged muscular contraction. Its inhibitory effects on gastric smooth muscles, in theory, make it a potential agent for obesity treatment through delayed gastric emptying and increased satiety. This review aims to examine the evidence for the use of endoscopic BTX-A injection for treating obesity. The literature search identified 60 articles with 11 primary studies as relevant for the scope of the review. Several studies have been conducted to examine the effect of BTX-A injections on obesity, including both animal and human studies. Current evidence from identified studies does not demonstrate sustained weight loss through the use of endoscopic BTX-A injection.

KW - Botulinum toxin-A

KW - Endoscopy

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=85021960871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021960871&partnerID=8YFLogxK

U2 - 10.1007/s11695-017-2806-3

DO - 10.1007/s11695-017-2806-3

M3 - Review article

VL - 27

SP - 2471

EP - 2478

JO - Obesity Surgery

JF - Obesity Surgery

SN - 0960-8923

IS - 9

ER -